Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-06-12 | BIOCRYST PHARMACEUTICALS INC | SANDERS MACHELLE
(Director) |
A | Common Stock | A | 6820 | $0.00 - $0.00 | $0 |
| 2024-06-12 | BIOCRYST PHARMACEUTICALS INC | LEVIN ALAN G
(Director) |
A | Common Stock | A | 6820 | $0.00 - $0.00 | $0 |
| 2024-06-12 | BIOCRYST PHARMACEUTICALS INC | Hutson Nancy J
(Director) |
A | Common Stock | A | 6820 | $0.00 - $0.00 | $0 |
| 2024-06-14 | BIOCRYST PHARMACEUTICALS INC | HEGGIE THERESA
(Director) |
S | Common Stock | D | 6698 | $6.11 - $6.11 | $40,924 |
| 2024-06-12 | BIOCRYST PHARMACEUTICALS INC | HEGGIE THERESA
(Director) |
A | Common Stock | A | 6820 | $0.00 - $0.00 | $0 |
| 2024-06-12 | BIOCRYST PHARMACEUTICALS INC | ABERCROMBIE GEORGE B
(Director) |
A | Common Stock | A | 6820 | $0.00 - $0.00 | $0 |
| 2024-05-30 | BIOCRYST PHARMACEUTICALS INC | LEVIN ALAN G
(Director) |
P | Common Stock | A | 7861 | $6.36 - $6.36 | $49,995 |
| 2024-05-24 | BIOCRYST PHARMACEUTICALS INC | ASELAGE STEVE
(Director) |
P | Common Stock | A | 2500 | $6.40 - $6.40 | $16,000 |
| 2024-05-20 | BIOCRYST PHARMACEUTICALS INC | Hutson Nancy J
(Director) |
P | Common Stock | A | 5000 | $6.38 - $6.38 | $31,900 |
| 2024-05-20 | BIOCRYST PHARMACEUTICALS INC | MILANO VINCENT
(Director) |
P | Common Stock | A | 15000 | $6.25 - $6.25 | $93,750 |
| 2024-05-14 | BIOCRYST PHARMACEUTICALS INC | Thackray Helen M.
(Chief R&D Officer) |
P | Common Stock | A | 30000 | $5.86 - $5.86 | $175,800 |
| 2024-05-13 | BIOCRYST PHARMACEUTICALS INC | Galson Steven K
(Director) |
P | Common Stock | A | 21940 | $5.49 - $5.49 | $120,450 |
| 2024-05-13 | BIOCRYST PHARMACEUTICALS INC | Barnes Alane P
(Chief Legal Officer) |
P | Common Stock | A | 5000 | $5.53 - $5.53 | $27,650 |
| 2024-05-13 | BIOCRYST PHARMACEUTICALS INC | Stonehouse Jon P
(President & CEO) |
P | Common Stock | A | 30000 | $5.55 - $5.55 | $166,500 |
| 2024-05-13 | BIOCRYST PHARMACEUTICALS INC | Gayer Charles K
(Chief Commercial Officer) |
P | Common Stock | A | 30000 | $5.47 - $5.47 | $164,100 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |